The human adenoviral vector platform, on which the Sputnik V vaccine is based, is almost nine times more reliable than the non-human adenovirus platform.
The survey was conducted from October 9-19 by YouGov, a leading UK research data and analytics group. It included people from Brazil, Vietnam, Egypt, India, Indonesia, Malaysia, Mexico, Nigeria, UAE, Saudi Arabia and the Philippines. More than 2.5 billion people live in these countries, or over 30% of the world’s population. The survey became one of the largest on this topic and the first global survey involving the countries of the Middle East and Southeast Asia.
The survey was conducted prior to the announcement that the Sputnik V vaccine is 92% effective at protecting people from COVID-19, according to interim trial results.
Key survey results in India
- The overwhelming majority of trial participants are positive about vaccination against the coronavirus (80% of the respondents).
- Among those who are aware of the Russian Sputnik V vaccine, the percentage of those who are willing to be vaccinated is even higher – over 85% of those surveyed.
- 60% of the respondents are aware of Russia’s Sputnik V vaccine – the highest awareness level among the countries that participated in the survey, on par with respondents from Mexico.
- In India, there is high confidence in the human adenovirus vaccine (Sputnik V platform) as 9 out of 10 vaccine respondents preferred this platform over non-human adenovirus platforms.
- Russia ranks first among foreign vaccine-manufacturing countries, which were mentioned by respondents primarily as the most trustworthy. Overall, 5 out of 10 respondents said that Russia is one of the most reliable countries (each respondent mentioned three countries).